Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...

To investigate whether Liraglutide had a neuroprotective after cardiac arrest and return of spontaneous circulation (CA/ROSC) and explore its potential mechanisms. Adopting an 8-min asphyxial cardiac ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers. Carsten Snejbjerg/Bloomberg via Getty Images ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

New research presented at the European Congress on Obesity (ECO 2025) and published in the journal Diabetes, Obesity and ...

Learn how GLP-1 receptor agonists show promise in reducing alcohol consumption and aiding weight loss in obesity treatment.

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four ...

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and ...

New research suggests that weight loss injections, also known as GLP-1 receptor agonists, may have a significant anti-cancer ...